08/14/2025 10:26 AM | JANUS HENDERSON GROUP PLC (Filed by) Janux Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
08/12/2025 8:05 AM | Adage Capital Management, L.P. (Filed by) Janux Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
07/17/2025 6:54 PM | BlackRock, Inc. (Filed by) Janux Therapeutics (Subject)
| Form SCHEDULE 13G | |
06/13/2025 6:30 PM | Janux Therapeutics (Issuer) Kung Winston (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/13/2025 6:30 PM | Janux Therapeutics (Issuer) Simson Jake (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/13/2025 6:30 PM | Janux Therapeutics (Issuer) McNulty Alana B. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/13/2025 6:30 PM | Hernday Natasha (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/13/2025 6:30 PM | Gujrathi Sheila (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/13/2025 6:30 PM | DOBMEIER ERIC (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/13/2025 6:30 PM | CAPPS VICKIE L (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/13/2025 6:30 PM | Barrett Ronald W (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for JANX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
06/13/2025 6:33 PM | Janux Therapeutics (Issuer) Kolchinsky Peter (Reporting) RA Capital Healthcare Fund LP (Reporting) RA CAPITAL MANAGEMENT, L.P. (Reporting) RA Capital Nexus Fund II, L.P. (Reporting) Shah Rajeev M. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/04/2025 7:00 PM | Doyle Janeen Noel (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/23/2025 7:02 PM | Doyle Janeen Noel (Reporting) Janux Therapeutics (Issuer)
| Form 3 Initial statement of beneficial ownership of securities | |
05/14/2025 11:25 AM | JANUS HENDERSON GROUP PLC (Filed by) Janux Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
05/08/2025 3:30 PM | Janux Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/02/2025 7:00 PM | Janux Therapeutics (Issuer) Meyer Andrew Hollman (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/25/2025 3:39 PM | Janux Therapeutics (Filer)
| Form DEF 14A | |
04/25/2025 3:40 PM | Janux Therapeutics (Filer)
| Form DEFA14A | |
04/25/2025 3:45 PM | Janux Therapeutics (Filer)
| Form ARS | |
04/23/2025 7:00 PM | Janux Therapeutics (Issuer) Meyer Andrew Hollman (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/21/2025 3:18 PM | Janux Therapeutics (Subject) Meyer Andrew Hollman (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/10/2025 3:33 PM | Janux Therapeutics (Subject) RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SCHEDULE 13D/A | |
03/07/2025 5:05 PM | Janux Therapeutics (Issuer) Kolchinsky Peter (Reporting) RA Capital Healthcare Fund LP (Reporting) RA CAPITAL MANAGEMENT, L.P. (Reporting) RA Capital Nexus Fund II, L.P. (Reporting) Shah Rajeev M. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/05/2025 7:00 PM | Janux Therapeutics (Issuer) Meyer Andrew Hollman (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/27/2025 3:53 PM | Janux Therapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/27/2025 3:55 PM | Janux Therapeutics (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/14/2025 3:41 PM | Janux Therapeutics (Subject) Paradigm Biocapital Advisors LP (Filed by)
| Form SCHEDULE 13G/A | |
02/14/2025 10:24 AM | JANUS HENDERSON GROUP PLC (Filed by) Janux Therapeutics (Subject)
| Form SCHEDULE 13G | |
02/12/2025 8:30 AM | Adage Capital Management, L.P. (Filed by) Janux Therapeutics (Subject)
| Form SCHEDULE 13G | |
02/05/2025 7:00 PM | Janux Therapeutics (Issuer) Meyer Andrew Hollman (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/08/2025 7:00 PM | Campbell David Alan (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/07/2025 3:11 PM | Campbell David Alan (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/03/2025 7:00 PM | Janux Therapeutics (Issuer) McIver Zachariah (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
01/03/2025 7:01 PM | Janux Therapeutics (Issuer) Winter Charles M. (Reporting)
| Form 3/A | |
01/03/2025 7:10 PM | Dobek Maria (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/03/2025 7:10 PM | DiRaimondo Thomas (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/03/2025 7:10 PM | Janux Therapeutics (Issuer) Robinson Byron (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/03/2025 7:10 PM | Campbell David Alan (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/03/2025 7:10 PM | Janux Therapeutics (Issuer) Winter Charles M. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/03/2025 7:10 PM | Janux Therapeutics (Issuer) McIver Zachariah (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
Altucher: It Looks Like My Trump prediction is coming true (Ad) New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun.
Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. See Altucher’s Trump crypto prediction here |
12/27/2024 7:00 PM | Campbell David Alan (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/26/2024 9:00 AM | Campbell David Alan (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/20/2024 5:25 PM | Janux Therapeutics (Issuer) Meyer Andrew Hollman (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/05/2024 3:32 PM | Janux Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/05/2024 3:28 PM | Janux Therapeutics (Filer)
| Form 424B5 | |
12/03/2024 7:00 PM | Campbell David Alan (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/02/2024 4:10 PM | Janux Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/27/2024 7:00 PM | Campbell David Alan (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/14/2024 3:24 PM | BIOTECHNOLOGY VALUE FUND L P (Filed by) Janux Therapeutics (Subject)
| Form SC 13G/A | |
11/08/2024 4:58 PM | Avalon Ventures XI, L.P. (Filed by) Janux Therapeutics (Subject)
| Form SC 13D/A | |
11/07/2024 6:08 PM | CAPPS VICKIE L (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/07/2024 6:09 PM | Gujrathi Sheila (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/06/2024 3:23 PM | Janux Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/06/2024 3:07 PM | Janux Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/01/2024 4:05 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024 4:02 PM | Janux Therapeutics (Subject) Lichter Jay (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024 3:24 PM | Avalon BioVentures SPV I, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024 3:30 PM | Avalon Ventures XI, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024 3:17 PM | Avalon BioVentures I, LP (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024 3:07 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/30/2024 6:30 PM | Campbell David Alan (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/28/2024 3:46 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024 4:28 PM | Avalon Ventures XI, L.P. (Filed by) Janux Therapeutics (Subject)
| Form SC 13D/A | |
10/25/2024 3:57 PM | Avalon Ventures XI, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024 3:44 PM | Avalon BioVentures SPV I, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024 3:51 PM | Avalon BioVentures I, LP (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024 11:37 AM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144/A | |
10/24/2024 4:53 PM | Janux Therapeutics (Subject) Lichter Jay (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/24/2024 4:04 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/24/2024 3:15 PM | Janux Therapeutics (Issuer) Lichter Jay (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/23/2024 4:59 PM | Avalon BioVentures SPV I, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024 4:38 PM | Avalon BioVentures I, LP (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024 4:39 PM | Janux Therapeutics (Subject) Paradigm Biocapital Advisors LP (Filed by)
| Form SC 13G | |
10/23/2024 4:07 PM | Avalon Ventures XI, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024 3:36 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024 3:20 PM | Janux Therapeutics (Issuer) Kolchinsky Peter (Reporting) RA Capital Healthcare Fund LP (Reporting) RA CAPITAL MANAGEMENT, L.P. (Reporting) RA Capital Nexus Fund II, L.P. (Reporting) Shah Rajeev M. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/22/2024 3:16 PM | Avalon Ventures XI, L.P. (Filed by) Janux Therapeutics (Subject)
| Form SC 13D/A | |
10/22/2024 3:17 PM | Janux Therapeutics (Subject) RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
10/21/2024 3:43 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024 3:25 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024 12:39 PM | Janux Therapeutics (Subject) Lichter Jay (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024 5:51 PM | Avalon BioVentures I, LP (Reporting) Avalon BioVentures SPV I, L.P. (Reporting) Avalon Ventures XI, L.P. (Reporting) Janux Therapeutics (Issuer) Lichter Jay (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/18/2024 3:57 PM | Avalon Ventures XI, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024 3:39 PM | Avalon BioVentures SPV I, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024 3:48 PM | Avalon BioVentures I, LP (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024 4:06 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024 3:24 PM | Janux Therapeutics (Subject) Lichter Jay (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024 3:18 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024 5:14 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024 4:35 PM | Avalon BioVentures I, LP (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Trump’s national nightmare is here (Ad) Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II.
They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. Watch the National Emergency broadcast here |
10/16/2024 4:28 PM | Janux Therapeutics (Subject) Lichter Jay (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024 4:25 PM | Avalon BioVentures SPV I, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024 4:17 PM | Avalon Ventures XI, L.P. (Reporting) Janux Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024 4:10 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/30/2024 7:49 PM | Avalon BioVentures I, LP (Reporting) Avalon BioVentures SPV I, L.P. (Reporting) Avalon Ventures XI, L.P. (Reporting) Janux Therapeutics (Issuer) Lichter Jay (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/30/2024 4:29 PM | Janux Therapeutics (Subject) Reardon Tighe (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/30/2024 4:34 PM | Janux Therapeutics (Subject) Lichter Jay (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024 6:30 PM | Campbell David Alan (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/27/2024 6:31 PM | DiRaimondo Thomas (Reporting) Janux Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |